247 related articles for article (PubMed ID: 25265432)
1. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
2. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.
Metcalf RA; Zhao S; Anderson MW; Lu ZS; Galperin I; Marinelli RJ; Cherry AM; Lossos IS; Natkunam Y
Mod Pathol; 2010 Mar; 23(3):420-33. PubMed ID: 20062012
[TBL] [Abstract][Full Text] [Related]
3. Expression of D-type cyclins in normal and neoplastic rat pituitary.
Qian X; Kulig E; Jin L; Lloyd RV
Endocrinology; 1998 Apr; 139(4):2058-67. PubMed ID: 9528994
[TBL] [Abstract][Full Text] [Related]
4. Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Ngo BT; Felthaus J; Hein M; Follo M; Wider D; Ihorst G; Engelhardt M; Wäsch R
Leuk Lymphoma; 2010 Sep; 51(9):1632-42. PubMed ID: 20578819
[TBL] [Abstract][Full Text] [Related]
5. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR.
Htwe SS; Maeda M; Matsumoto R; Sakamoto N; Murakami S; Yamamoto S; Katoh M; Kumagai N; Hayashi H; Nishimura Y; Ohkura M; Wada H; Taniwaki M; Sugihara T; Otsuki T
Int J Mol Med; 2011 Jun; 27(6):789-94. PubMed ID: 21399865
[TBL] [Abstract][Full Text] [Related]
6. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.
Athanasiou E; Kaloutsi V; Kotoula V; Hytiroglou P; Kostopoulos I; Zervas C; Kalogiannidis P; Fassas A; Christakis JI; Papadimitriou CS
Am J Clin Pathol; 2001 Oct; 116(4):535-42. PubMed ID: 11601138
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
[TBL] [Abstract][Full Text] [Related]
10. Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.
Blanca Pedregosa AM; Sánchez-González Á; Carrasco Valiente J; Ruiz García JM; Gómez Gómez E; López Beltrán A; Requena Tapia MJ
Actas Urol Esp; 2017 Apr; 41(3):172-180. PubMed ID: 27726892
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
12. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
13. Selective usage of D-type cyclins in lymphoid malignancies.
Suzuki R; Kuroda H; Komatsu H; Hosokawa Y; Kagami Y; Ogura M; Nakamura S; Kodera Y; Morishima Y; Ueda R; Seto M
Leukemia; 1999 Sep; 13(9):1335-42. PubMed ID: 10482983
[TBL] [Abstract][Full Text] [Related]
14. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
15. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.
Cao X; Fan L; Fang C; Zhu DX; Dong HJ; Wang DM; Wang YH; Xu W; Li JY
Med Oncol; 2012 Jun; 29(2):1190-6. PubMed ID: 21479697
[TBL] [Abstract][Full Text] [Related]
16. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
17.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
18. Cyclin alterations in giant cell tumor of bone.
Kauzman A; Li SQ; Bradley G; Bell RS; Wunder JS; Kandel R
Mod Pathol; 2003 Mar; 16(3):210-8. PubMed ID: 12640100
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
[TBL] [Abstract][Full Text] [Related]
20. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]